The highest olaparib concentration that was tested is 10µM and this value was assigned to olaparib insensitive cell lines.
Other HNSCC display signs of FANCD2-monoubiquitylation, even in untreated conditions, and shows FA activation by endogenous sources (replication stress) and is typical for tumor cells. Other HNSCC lack FANCD2-monoubiquitylation (FANCD2-L band). If however sensitive to MMC, one can assume effi cient drug activation and this therefore shows the inability to monoubiquitylate FANCD2, such as in the UT-SCC-43A.
Supplementary Figure 6: rad51 foci formation after radiation. Radiation-induced RAD51 foci histograms in UT-SCC-60B
(a) and UT-SCC-30 (B). The percentage of cells with rad51foci counts in the indicated bins are shown. In HR-profi cient cells radiation (6 Gy) induces the formation of nuclear rad51foci. The data show a pronounced induction of such rad51 foci in the UT-SCC-30 and a greatly dampened response in the UT-SCC-60B. This is consistent with the MMC-hypersensitivity and indicates a compromised FA/HR pathway in the UT-SCC-60B. The average of data of 3-5 independent experiments are shown (error = SD). Cells were seeded in 6-well plates containing sterilized microscope cover slips and irradiated with 6Gy. After 5 hours, cells were fi xed with 4% paraformaldehyde, permeablized with 0.15% Triton-X and incubated in 1% BSA. Rad51 labelling was performed by overnight incubation with rabbit anti-RAD51 primary antibody (polyclonal H29, Santa Cruz), followed by a FITC labelled anti-rabbit secondary antibody (Jackson ImmunoResearch) . Images were collected for counting with the Leica TCS SP5 Confocal microscope at 63× or 100× magnifi cation. As shown, UT-SCC-30 which contains a variant in BRCA1, is capable of RAD51 foci formation, indicating an intact repair pathway. This is in accordance with functional BRCA.
Supplementary Figure 7:
indications for loss of heterozygosity in selected genes. Lolliplot diagrams to the left show the variant zygosity distribution in genes of cell lines that were classifi ed as having a FA/HR variant (marked with * ) according to our variant selection protocol. In addition to these variants, all other SNV variants (originally discarded by the variant selection protocol), but with MAF below 60%, are shown. Homozygous variants are shown in red, heterozygous variants in red and yellow. Estimated copy number across all baits in the capture and plotted in chromosomal order (bait No. on the X-axis) are shown to the right for the respective HNSCC line. Red circle and arrow highlight the position of the affected gene as indicated to the left. Figure 4D . In-fi gure: hazard ratios (HR) from Cox proportional hazards models with univariate p-values from the exact logrank test. Multivariate HR and p-values from Cox models that include the tested gene set, tumor site, HPV-status and tumor volume are also shown for comparison purposes, however it should be noted that small number of events per variable result in inaccurate parameter estimates and restricts meaningful multivariate analyses. The number of LRC events were 3 for affected and 7 for non-affected.
Supplementary

Supplementary Figure 11: association of somatic Fa/Hr gene variants with clinical outcome. (a) Somatic variant calling
in our patient cohort identifi ed 22/77 patient tumors with somatic FA/HR-variants. The somatic variants were not associated with overall survival, showing that common approach of selecting somatic variants would have missed the clinical outcome associations presented in this study. Only variants in exonic and splice site regions were considered. SNP databases were used to remove germline variants, because matched normal samples were unavailable. Variants were considered somatic if they (1) were absent in all three of the 1000 Genomes Project, Exome Sequencing Project or Exome Aggregation Consortium databases, or (2) if they occurred >20 times in the COSMIC database. (B) From the somatic FA/HR-variants identifi ed in (A), only those predicted to be deleterious (by SIFT or polyphen) or truncating (frameshift and non-frameshift indels, stop gain and loss variants) were selected. This analysis identifi ed 15/77 patient tumors with deleterious or truncating somatic FA/HR variants. These patient tumors did not have a different outcome than the others. In-fi gure multivariate hazard ratios (HR) come from multivariate Cox proportional hazard models that include the tested gene set, tumor site, HPV-status and tumor volume. List of used HNSCC cell lines generated and provided by R. Grenamn and the determined cellular characteristics and response parameters. The FA patient-derived fi broblast cell lines with known mutations in FANCG (EUFA 636)(25) and FANCA (VU0173-F; EUFA 173)(24) were kindly provided by Dr. H. Joenje and served as positive controls, whereas an hTERT transformed human fi broblast cell line (GM847), was included for comparison in a non-tumor derived cell line. The FA gene mutation status in the FANCA and FANCG positive control cell lines was confi rmed by PCR and subsequent conventional Sanger sequencing and by capture based sequencing that replicated these results. Doubling times of all cell lines were assessed by plating different cell numbers into 6-well plates in triplicates and counting live cells after harvesting them by trypsinization at different time points thereafter. Population doubling times (DT) were calculated from the exponential fi ts on the steepest part of the growth curves. Radiation survival data were kindly provided by R. Grènman. * = IC 50 was not achieved within the tested dose range; the maximum tested olaparib concentration was assigned to these cell lines. NDT = not determined, sd = standard deviation, AUC = Area under the radiation survival curve, SF2 = surviving fraction at 2Gy, N = number of independent experiments. # all cell lines were regularly tested for mycoplasma ( Janetzko et al, Transfus Med Hemother 2014; 41(1):83-89) twice a month when in culture. Passage number never exceeded 20. Photographs, morphology, cell doubling , PE, characteristics and later DNA-Seq served as authentication method. 
Supplementary
ENSG00000196584 List of canonical FA/HR pathway genes with core activities in the Fanconi anemia and homologous recombination DNA repair pathways that were chosen for the genetic analyses in this study. Canonical FA and HR pathway genes that were available within the sequencing capture set were selected and are listed with their ENSEMBL reference IDs. RefSeq to be in (ncRNA) exonic or splicing regions were selected. Variant calls were fi ltered against the following criteria: at least 10 total reads and 4 reads containing the variant allele pass the quality controls, and at least 80% of all reads need to contain the variant allele (variant allele frequency, VAF, of > 0.8). Since assuming loss of gene function to primarily cause the observed DNA repair defects we focused on variants with such a high read fraction, as this is thought to refl ect homozygosity. Only rare polymorphisms were retained. This was done by removing variants with a minor allele frequency (MAF) higher than 2.5% in the 1000 Genomes database. Variants that were not present in this database were considered rare or de novo, hence retained. Splicing variants were removed if they were not in COSMIC70. Finally, variants that occurred in two or more of four healthy control subjects that were included in the sequencing analysis were removed. Identifi ed variants were individually confi rmed using IGV viewer. * Cut offs were chosen based on HNSCC risk estimates as described in discussion. ** After applying sample specifi c corrections that considered the pathologist's tumour percentage estimates in the sample as described in Materials and Methods. PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) is a tool that predicts a possible impact of an amino acid change on the protein structure. SIFT (http://sift.jcvi.org/) prediction is based on the degree of conversation of aminoacids in the sequence. CADD (http://cadd.gs.washington.edu/) and REVEL (https://sites.google.com/site/ revelgenomics/) are variant effect prediction algorithms that combine the knowledge of a multitude of algorithms such as PolyPhen-2 and SIFT. CADD and REVEL scores above 15 and 0.5, respectively, are considered pathogenic. T = Tolerated; B = Benign; PMID = reference PubMed ID number. Minor allele frequencies (MAF) from 1000 genome (1000G) are listed. Table shows 
